Menozzi, Elisa;
Schapira, Anthony HV;
(2025)
Prospects for Disease Slowing in Parkinson Disease.
Annual Review of Pharmacology and Toxicology
, 65
pp. 237-258.
10.1146/annurev-pharmtox-022124-033653.
Preview |
Text
annurev-pharmtox-022124-033653.pdf - Published Version Download (301kB) | Preview |
Abstract
The increasing prevalence of Parkinson disease (PD) highlights the need to develop interventions aimed at slowing or halting its progression. As a result of sophisticated disease modeling in preclinical studies, and refinement of specific clinical/genetic/pathological profiles, our understanding of PD pathogenesis has grown over the years, leading to the identification of several targets for disease modification. This has translated to the development of targeted therapies, many of which have entered clinical trials. Nonetheless, up until now, none of these treatments have satisfactorily shown disease-modifying effects in PD. In this review, we present the most up-to-date disease-modifying pharmacological interventions in the clinical trial pipeline for PD. We focus on agents that have reached more advanced stages of clinical trials testing, highlighting both positive and negative results, and critically reflect on strengths, weaknesses, and challenges of current disease-modifying therapeutic avenues in PD.
| Type: | Article |
|---|---|
| Title: | Prospects for Disease Slowing in Parkinson Disease |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1146/annurev-pharmtox-022124-033653 |
| Publisher version: | https://doi.org/10.1146/annurev-pharmtox-022124-03... |
| Language: | English |
| Additional information: | Copyright © 2025 by the author(s). This work is licensed under a Creative Commons Attribution 4.0 International License, https://creativecommons.org/licenses/by/4.0/deed.en, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See credit lines of images or other third-party material in this article for license information. |
| Keywords: | Parkinson disease, disease progression, disease modifying, α-synuclein, genetics |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Movement Neurosciences |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10204950 |
Archive Staff Only
 |
View Item |
